Výsledky vyhledávání

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

Autor: J Sany, L. B. A. Van De Putte, C Atkins, J. W. J. Bijlsma, N Walter, Michel Malaise, L. Settas, Peter Nash, S Fischkoff, M Kaul, S Todesco, Maxime Dougados, P.L.C.M. van Riel, H Kupper, Paul Emery, Anthony S. Russell

Publikováno v: Annals of the Rheumatic Diseases. 63:508-516

Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for whom previous DMARD treatment has failed. Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were random

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a94882d37721bb4014945317a7ea876
https://doi.org/10.1136/ard.2003.013052

Zobrazit plný text záznamu

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies

Autor: Sharyn D. Baker, Eric K. Rowinsky, Raja Velagapudi, B Razvillas, S Fischkoff, S. G. Eckhardt, D Toppmeyer, R Fram, D. D. Von Hoff, Maura Kraynak, Lisa A. Hammond, C. Aylesworth, K Jakimowicz, Miguel A. Villalona-Calero

Publikováno v: Journal of Clinical Oncology. 16:2770-2779

PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic profile of the dolastatin 15 analog LU103793 when administered daily for 5 days every 3 weeks. PATIENTS AND METHODS Fifty-six courses of LU103

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94560091f0a5d0874eaebcbebaa2be28
https://doi.org/10.1200/jco.1998.16.8.2770

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial)

Autor: Michael H. Weisman, C. Birbara, Harold E. Paulus, E.C. Keystone, Michael E. Weinblatt, Daniel E. Furst, S Fischkoff, Elliot Chartash

Publikováno v: Speaker abstracts 2001.

Background Objectives To investigate the clinical efficacy and safety of adalimumab (D2E7), given subcutaneously in combination with methotrexate (MTX) to rheumatoid arthritis (RA) patients who are partial responders to MTX treatment. Methods The ARM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01ec011d1520820695da67e2e751f4a9
https://doi.org/10.1136/annrheumdis-2001.1216

Zobrazit plný text záznamu